SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells. 2017

Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
Laboratory of Clinical Biology and Pharmacogenomics and Center for Clinical Research and Genomics, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.

Overcoming drug resistance is an important task for investigators and clinician to achieve successful chemotherapy in cancer patients. Drug resistance is caused by various factors, including the overexpression of P-glycoprotein (P-gp, MDR1). The development of new, useful compounds that overcome drug resistance is urgent. SH003 is extracted from the mixture of three different herbs, and its anticancer effect has been revealed in different cancer cell types. In the present study, we investigated whether SH003 is able to reverse drug resistance using paclitaxel-resistant breast cancer cells (MCF-7/PAC). In our experiments, SH003 significantly decreased cell growth and colony formation in MCF-7/PAC cells and parental MCF-7 cells. This growth inhibition was related to the accumulation of cells in the sub-G0/G1 apoptotic population and an increase in the number of apoptotic cells. SH003 reduced the mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated proteins (MRPs) in MCF-7/PAC cells. SH003 also down-regulated the expression of P-gp. SH003 reversed drug efflux from MCF-7/PAC cells, resulting in rhodamine123 (Rho123) accumulation. Inhibition of drug resistance by SH003 is related to the suppression of the signal transducer and activator of transcription 3 (STAT3) signaling pathway. SH003 decreased STAT3 activation (p-STAT3) and its nuclear translocation and inhibited the secretion of VEGF and MMP-2, which are STAT3 target genes. An STAT3 inhibitor, JAK inhibitor I and an HIF-1α inhibitor decreased cell growth in MCF-7 and MCF-7/PAC cells. Taken together, these results demonstrate that SH003 can overcome drug resistance, and SH003 might be helpful for chemotherapy in cancer patients.

UI MeSH Term Description Entries
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014410 Tumor Stem Cell Assay A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents. Clonogenic Cell Assay, Tumor,Colony-Forming Units Assay, Tumor,Neoplasm Stem Cell Assay,Stem Cell Assay, Tumor,Colony Forming Units Assay, Tumor
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D050796 STAT3 Transcription Factor A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-6 family members. STAT3 is constitutively activated in a variety of TUMORS and is a major downstream transducer for the CYTOKINE RECEPTOR GP130. APRF Transcription Factor,Acute-Phase Response Factor,IL6-Response Factor,LIF-Response Factor,STAT3 Protein,STAT3a Transcription Factor,STAT3b Transcription Factor,Signal Transducer and Activator of Transcription 3,Stat3alpha Transcription Factor,Stat3beta Transcription Factor,Acute Phase Response Factor,IL6 Response Factor,LIF Response Factor,Response Factor, Acute-Phase,Transcription Factor, APRF,Transcription Factor, STAT3,Transcription Factor, STAT3a,Transcription Factor, STAT3b,Transcription Factor, Stat3alpha,Transcription Factor, Stat3beta

Related Publications

Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
October 2013, JAK-STAT,
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
May 2015, Human reproduction (Oxford, England),
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
November 2010, Molecular pharmacology,
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
August 2007, Molecular carcinogenesis,
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
January 2011, American journal of cancer research,
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
March 2012, Proceedings of the National Academy of Sciences of the United States of America,
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
April 2013, European journal of medicinal chemistry,
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
December 2011, Bioorganic & medicinal chemistry,
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
April 2021, European journal of medicinal chemistry,
Hye-Sook Seo, and Jin Mo Ku, and Hee-Jae Lee, and Jong-Kyu Woo, and Chunhoo Cheon, and Mia Kim, and Bo-Hyoung Jang, and Yong Cheol Shin, and Seong-Gyu Ko
January 2002, Cancer research,
Copied contents to your clipboard!